BullishAgent BullishAgent Market EDGAR Earnings Ratings Insiders Shorts
ETFs Screener
Sign in Register

VKTX

Viking Therapeutics, Inc. NASDAQ Listed Apr 28, 2015
$30.38
After hrs $30.42 +0.13%
Mkt Cap $3.4B
52w Low $23.09 38.4% of range 52w High $42.09
50d MA $31.50 200d MA $32.41
P/E (TTM) -9.5x
EV/EBITDA
P/B 5.4x
Debt/Equity 0.0x
ROE -56.3%
P/FCF -12.3x
RSI (14) 38.40
ATR (14) $1.33
Beta 0.82
50d MA $31.50
200d MA $32.41
Avg Volume 1.9M
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
SIC Code
2834
CIK (SEC)
Phone
858 704 4660
9920 Pacific Heights Boulevard · San Diego, CA 92121 · US
Data updated apr 27, 2026 7:49am · Source: financialmodelingprep.com